Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy

Saved in:
Bibliographic Details
Published in:European urology open science (Online) 2022-11, Vol.45, p.S234-S235
Main Authors: Albert, F., Antoniewicz, A., Grantzow, T., Greis, A., Fingerle-Rowson, G., Ruf, P., Lindhofer, H., Kriegmair, M., Oberneder, R.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2666-1683
2666-1683
DOI:10.1016/S2666-1683(22)02578-2